Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents
Allergy · 2024-11 · 79 (11) · 2943-2952
DOI: 10.1111/all.16346 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Allergy, online erschienen am 12.10.2024. Verfasst von David J Jackson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK. Hauptthemen laut MEDLINE: Interleukin-5, Asthma, Receptors, Interleukin-5, Anti-Asthmatic Agents. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Eosinophilic asthma is characterized by frequent exacerbations, poor symptom control and accelerated lung function decline. It is now recognized that the immune response underlying eosinophilic asthma involves a complex network of interconnected pathways from both the adaptive and innate immune systems. Within this response, interleukin‐5 (IL‐5) plays a central role in eosinophil differentiation, activation and survival and has emerged as a key target for therapies treating severe asthma. The monoclonal antibodies mepolizumab and reslizumab target the ligand IL‐5, preventing its interaction with eosinophils; in contrast, benralizumab binds to the IL‐5 receptor (IL‐5R), preventing IL‐5 from binding and leading to substantially greater eosinophil reduction by enhanced antibody‐dependent cell‐mediated cytotoxicity. Although no direct head‐to‐head clinical trials of asthma have been published to formally evaluate the clinical significance of these different therapeutic approaches, the potential benefits of partial versus complete eosinophil depletion continue to remain an important area of study and debate. Here, we review the existing real‐world and clinical study data of anti‐IL‐5/anti‐IL‐5R therapies in severe eosinophilic asthma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK.
- School of Immunology & Microbial Sciences, King's College London, London, UK.
- Department of Medicine, National Jewish Health, Denver, Colorado, USA.
- Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
- Pulmonary Department, Mainz University Hospital, Mainz, Germany.
ORCID-Profile: David J Jackson
Förderung
- AstraZeneca
Zitieren
APA
Jackson, D. J., Wechsler, M. E., Brusselle, G., & Buhl, R. (2024). Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents. Allergy, 79(11), 2943-2952. https://doi.org/10.1111/all.16346
Vancouver
Jackson DJ, Wechsler ME, Brusselle G, Buhl R. Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents. Allergy. 2024;79(11):2943-2952. doi:10.1111/all.16346
BibTeX
@article{Jackson2024,
author = {Jackson, David J and Wechsler, Michael E and Brusselle, Guy and Buhl, Roland},
title = {Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents},
journal = {Allergy},
year = {2024},
volume = {79},
number = {11},
pages = {2943--2952},
doi = {10.1111/all.16346}
}
EUVIMED